advertisement
ATC Level5: V03AF01 - Mesna
ATC Level1:
ATC Level2:
- V03 - All other therapeutic products
ATC Level3:
- V03A - All other therapeutic products
ATC Level4:
- V03AF - Detoxifying agents for antineoplastic treatment
ATC Level5:
Drugs in ATC category "V03AF01":
- Ausobronc
- Delinar
- Filesna
- HS-CoM
- Holoxan Uromitexan
- Ifex / Mesnex Kit
- Ifex-M
- Ifomid-M
- Ifosfamide / Mesna Kit
- Ifoxan with Mesna
- Isoxan
- Mescryo
- Mesna (Mesna)
- 1 INDICATIONS AND USAGE MESNEX is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: MESNEX is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. MESNEX is a cytoprotective agent...
- Mesnex
- This medication is used to reduce the risk of bleeding in the bladder (hemorrhagic cystitis), which is a very serious side effect of treatment with a cancer chemotherapy drug called ifosfamide . Mesna helps to protect the lining of the bladder against damage from ifosfamide. The body breaks down ifosfamide to form a product that can harm the bladder, and mesna works by making this product less harmful. However, mesna does not change ifosfamide's anti-cancer effects. OTHER USES: This...
- Mesnil
- Mesodal
- Mestian
- Mexan
- Mistabron
- Mistabronco
- Mitexan
- Mucofluid
- Mucolene
- Neper
- Uromes
- Uromitexan Multidose
- Uromitexan
- Mesna is used to protect the bladder against some of the harmful effects of certain cancer medications known as oxazaphosphorines (e.g., cyclophosphamide, ifosfamide). After injection, mesna stays in the blood and is quickly moved to the kidney. Once in the kidney, it attaches to the byproducts of cancer medications that can cause harm to the bladder, making them harmless. Your doctor may have suggested this medication for conditions other than those listed in these drug information...
- Uroprot
- Varimesna
- Ziken
advertisement
The information was verified by Dr. Rachana Salvi, MD Pharmacology
© 2002 - 2024 "sdrugs.com". All Rights Reserved